vTv Therapeutics Inc. (VTVT)
Health Care · Diabetes therapeutics / endocrinology drugs · Nasdaq
A late-stage biopharmaceutical company developing cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials for type 1 diabetes, with FDA Breakthrough Therapy designation.
What vTv Therapeutics Inc. does
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's lead program is cadisegliatin (TTP399), a novel small-molecule liver-selective glucokinase activator currently in Phase 3 clinical trials as an adjunctive therapy to insulin for type 1 diabetes, which received FDA Breakthrough Therapy designation in 2021. The company is advancing clinical development through the CATT1 Phase 3 trial and expanding to a Phase 2 study in type 2 diabetes patients in partnership with G42 Investments.
Themes: ["Type 1 diabetes treatment","Type 2 diabetes treatment","Glucokinase activators","Metabolic disease","Hypoglycemia reduction","Inflammatory disease"]
Fundamentals
- Price$33.49 as of 2026-07-10 close
- Market cap$128M as of 2026-07-13
- 1-year return-69.6% as of 2026-07-10 close
- P/E56.65 as of 2026-07-13
- Net margin+65.5% as of 2026-07-13
- ROE+4.0% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)+216600.0% as of 2026-07-13
- Beta0.28 as of 2026-07-13
Key risks (from latest filing)
["Clinical development risks: cadisegliatin previously faced a clinical hold from July 2024 to March 2025 due to radiochromatographic signal concerns in the ADME study, which could recur and delay or halt development programs.","Regulatory and approval risk: the company depends heavily on the Phase 3 CATT1 trial and future registrational studies for cadisegliatin approval; failure to meet endpoints or adverse safety signals could prevent market authorization.","Funding dependency: the company's operations depend on securing additional capital for clinical trials and development; market conditions or investor sentiment changes could limit funding availability."]
Competitors & peers
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Sanofi (SNF)
- Mannkind Corporation (MNKD)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.